Amy K Patick

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. pmc Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers
    Frederick G Hayden
    Department of Internal Medicine, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA
    Antimicrob Agents Chemother 47:3907-16. 2003
  2. pmc Identification and characterization of UK-201844, a novel inhibitor that interferes with human immunodeficiency virus type 1 gp160 processing
    Wade S Blair
    Pfizer Global Research and Development, La Jolla Laboratories, San Diego, CA 92121, USA
    Antimicrob Agents Chemother 51:3554-61. 2007
  3. pmc In vitro resistance study of AG-021541, a novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase
    Stephanie T Shi
    Department of Virology, Pfizer Global Research and Development, La Jolla Laboratories, 10777 Science Center Drive, San Diego, CA 92121, USA
    Antimicrob Agents Chemother 52:675-83. 2008
  4. ncbi request reprint Rhinovirus chemotherapy
    Amy K Patick
    Pfizer Global Research and Development, La Jolla Laboratories, San Diego, CA 92121, USA
    Antiviral Res 71:391-6. 2006
  5. pmc In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease
    Amy K Patick
    Department of Virology, Pfizer Global Research and Development, 10777 Science Center Drive, San Diego, CA 92121, USA
    Antimicrob Agents Chemother 49:2267-75. 2005
  6. ncbi request reprint Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics
    Peter S Dragovich
    Pfizer Global Research and Development La Jolla, 10777 Science Center Drive, San Diego, CA 92121 1111, USA
    J Med Chem 46:4572-85. 2003
  7. ncbi request reprint Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 6. Structure-activity studies of orally bioavailable, 2-pyridone-containing peptidomimetics
    Peter S Dragovich
    Pfizer Global Research and Development La Jolla Agouron Pharmaceuticals, Inc, 10777 Science Center Drive, San Diego, California 92121 1111, USA
    J Med Chem 45:1607-23. 2002
  8. pmc Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase
    Stephanie T Shi
    Department of Cancer Biology, Pfizer Global Research and Development, La Jolla Laboratories, 10724 Science Center Drive, San Diego, CA 92121, USA
    Antimicrob Agents Chemother 53:2544-52. 2009
  9. ncbi request reprint Structure-based design of a parallel synthetic array directed toward the discovery of irreversible inhibitors of human rhinovirus 3C protease
    Theodore O Johnson
    Pfizer Global R and D La Jolla Agouron Pharmaceuticals, Inc, 10770 Science Center Road, San Diego, CA 92121, USA
    J Med Chem 45:2016-23. 2002
  10. pmc Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors
    Koleen J Herlihy
    Pfizer Global Research and Development, La Jolla Laboratories, 10724 Science Center Drive, San Diego, California 92121, USA
    Antimicrob Agents Chemother 52:3523-31. 2008

Collaborators

Detail Information

Publications20

  1. pmc Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers
    Frederick G Hayden
    Department of Internal Medicine, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA
    Antimicrob Agents Chemother 47:3907-16. 2003
    ..Results from these studies in experimental rhinoviral infection support continued investigation of intranasal ruprintrivir in the setting of natural HRV infection...
  2. pmc Identification and characterization of UK-201844, a novel inhibitor that interferes with human immunodeficiency virus type 1 gp160 processing
    Wade S Blair
    Pfizer Global Research and Development, La Jolla Laboratories, San Diego, CA 92121, USA
    Antimicrob Agents Chemother 51:3554-61. 2007
    ..Our results demonstrate that UK-201844 represents the prototype for a unique HIV-1 inhibitor class that directly or indirectly interferes with HIV-1 gp160 processing...
  3. pmc In vitro resistance study of AG-021541, a novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase
    Stephanie T Shi
    Department of Virology, Pfizer Global Research and Development, La Jolla Laboratories, 10777 Science Center Drive, San Diego, CA 92121, USA
    Antimicrob Agents Chemother 52:675-83. 2008
    ..The clinical relevance of in vitro resistance to HCV polymerase inhibitors remains to be investigated...
  4. ncbi request reprint Rhinovirus chemotherapy
    Amy K Patick
    Pfizer Global Research and Development, La Jolla Laboratories, San Diego, CA 92121, USA
    Antiviral Res 71:391-6. 2006
    ....
  5. pmc In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease
    Amy K Patick
    Department of Virology, Pfizer Global Research and Development, 10777 Science Center Drive, San Diego, CA 92121, USA
    Antimicrob Agents Chemother 49:2267-75. 2005
    ..These experiments highlight Compound 1 as a potent, orally bioavailable, irreversible inhibitor of HRV 3C protease and provide data that suggest that Cmax rather than the Cmin might be the key variable predicting clinical efficacy...
  6. ncbi request reprint Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics
    Peter S Dragovich
    Pfizer Global Research and Development La Jolla, 10777 Science Center Drive, San Diego, CA 92121 1111, USA
    J Med Chem 46:4572-85. 2003
    ..047-0.058 microM, mean vs seven HRV serotypes), and pharmacokinetics following oral administration (7 h dog plasma levels = 0.248-0.682 microM; 7 h CM-monkey plasma levels = 0.057-0.896 microM)...
  7. ncbi request reprint Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 6. Structure-activity studies of orally bioavailable, 2-pyridone-containing peptidomimetics
    Peter S Dragovich
    Pfizer Global Research and Development La Jolla Agouron Pharmaceuticals, Inc, 10777 Science Center Drive, San Diego, California 92121 1111, USA
    J Med Chem 45:1607-23. 2002
    ..05 microM) against multiple virus serotypes in cell culture. One 2-pyridone-containing 3CP inhibitor is shown to be bioavailable in the dog after oral dosing (F = 48%)...
  8. pmc Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase
    Stephanie T Shi
    Department of Cancer Biology, Pfizer Global Research and Development, La Jolla Laboratories, 10724 Science Center Drive, San Diego, CA 92121, USA
    Antimicrob Agents Chemother 53:2544-52. 2009
    ..Our results demonstrate that PF-00868554 has potent and broad-spectrum antiviral activity against genotype 1 HCV strains, supporting its use as an oral antiviral agent in HCV-infected patients...
  9. ncbi request reprint Structure-based design of a parallel synthetic array directed toward the discovery of irreversible inhibitors of human rhinovirus 3C protease
    Theodore O Johnson
    Pfizer Global R and D La Jolla Agouron Pharmaceuticals, Inc, 10770 Science Center Road, San Diego, CA 92121, USA
    J Med Chem 45:2016-23. 2002
    ..A crystal structure of one of the more potent inhibitors covalently bound to HRV-2 3CP is detailed. These compounds were also tested against HRV serotypes other than type 14 and were found to have highly variable activities...
  10. pmc Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors
    Koleen J Herlihy
    Pfizer Global Research and Development, La Jolla Laboratories, 10724 Science Center Drive, San Diego, California 92121, USA
    Antimicrob Agents Chemother 52:3523-31. 2008
    ..Our study demonstrates the utility of chimeric replicons for broad-spectrum activity determination of HCV inhibitors...
  11. doi request reprint Development of hepatitis C virus chimeric replicons for identifying broad spectrum NS3 protease inhibitors
    Joseph Binder
    Pfizer Worldwide Research and Development, San Diego, CA 92121, USA
    Antiviral Res 91:102-11. 2011
    ..This cell-based chimeric replicon system can be used to characterize the activities of protease inhibitors against diverse natural isolates and may improve the ability to predict dose and clinical efficacy...
  12. pmc New small-molecule inhibitor class targeting human immunodeficiency virus type 1 virion maturation
    Wade S Blair
    Pfizer Global Research and Development, La Jolla Laboratories, San Diego, California 921212, USA
    Antimicrob Agents Chemother 53:5080-7. 2009
    ..g., DSB), demonstrating that molecules of diverse chemical classes can inhibit this mechanism...
  13. pmc HIV capsid is a tractable target for small molecule therapeutic intervention
    Wade S Blair
    Pfizer Global Research and Development, La Jolla Laboratories, San Diego, California, United States of America
    PLoS Pathog 6:e1001220. 2010
    ..Our data demonstrate that broad-spectrum antiviral activity can be achieved by targeting this new binding site and reveal HIV CA as a tractable drug target for HIV therapy...
  14. pmc High-throughput human immunodeficiency virus type 1 (HIV-1) full replication assay that includes HIV-1 Vif as an antiviral target
    Joan Cao
    Department of Virology, Pfizer Global Research and Development, La Jolla Laboratories, 10777 Science Center Dr CB1, San Diego, CA 92121 1111, USA
    Antimicrob Agents Chemother 49:3833-41. 2005
    ..To our knowledge, this study represents the first example of an HIV-1 antiviral screen that includes Vif as a functional target and was executed on an industrial scale...
  15. ncbi request reprint Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. Part 7: structure-activity studies of bicyclic 2-pyridone-containing peptidomimetics
    Peter S Dragovich
    Pfizer Global Research and Development La Jolla Agouron Pharmaceuticals, Inc, San Diego, CA 92121 1111, USA
    Bioorg Med Chem Lett 12:733-8. 2002
    ..An optimized compound is shown to exhibit antiviral activity when tested against a variety of HRV serotypes (EC(50)'s ranging from 0.037 to 0.162 microM)...
  16. pmc Development of a novel dicistronic reporter-selectable hepatitis C virus replicon suitable for high-throughput inhibitor screening
    Weidong Hao
    Pfizer Global Research and Development, 10777 Science Center Drive, San Diego, CA 92121, USA
    Antimicrob Agents Chemother 51:95-102. 2007
    ..The development of a robust, high-throughput HCV replicon assay where the effects of inhibitors can be monitored for antiviral activity and cytotoxicity should greatly facilitate HCV drug discovery...
  17. ncbi request reprint A novel HIV-1 antiviral high throughput screening approach for the discovery of HIV-1 inhibitors
    Wade S Blair
    Department of Virology, Pfizer Global Research and Development, La Jolla Laboratories, 10777 Science Center Dr CB1, San Diego, CA 92121, USA
    Antiviral Res 65:107-16. 2005
    ....
  18. ncbi request reprint An optical thin film assay incorporating rhinovirus protease inhibitors as detector reagents
    Anna Ettinger
    Thermo Electron Corp, 331 South 104th Street, Louisville, CO 80027, USA
    Antiviral Res 61:153-9. 2004
    ..A rapid (20 min) OIA test was developed using a 15 atom spacer biotinylated inhibitor (4). Forty different HRV serotypes were studied and thirty three serotypes of these 40 were detected (80%)...
  19. ncbi request reprint In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor
    Akihiko Sato
    Shionogi Research Laboratories, Shionogi and Co, Ltd, Osaka 553 0002, Japan
    Antiviral Res 70:66-74. 2006
    ..4-5.4-fold increased susceptibility to CPV. Results also demonstrate that the CPV-resistance associated substitutions Y181C, F227C, F227L and L234I reverse the phenotypic resistance to AZT conferred by the T215Y substitution...
  20. pmc Potential use of antiviral agents in polio eradication
    Armando M De Palma
    University of Leuven, Leuven, Belgium
    Emerg Infect Dis 14:545-51. 2008
    ....